• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Arcadia Biosciences Inc.

    6/26/26 4:52:18 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples
    Get the next $RKDA alert in real time by email
    Form D
    FORM D
    Notice of Exempt Offering of Securities

    UNITED STATES SECURITIES
    AND EXCHANGE COMMISSION
    Washington, D.C.

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated Average burden hours per response: 4.0
    1. Issuer's Identity
    CIK (Filer ID Number)Previous Name(s)Checkbox checkedNoneEntity Type
    0001469443
    Radio button checkedCorporation
    Radio button not checked Limited Partnership
    Radio button not checked Limited Liability Company
    Radio button not checked General Partnership
    Radio button not checked Business Trust
    Radio button not checkedOther 
    Name of Issuer
     Arcadia Biosciences, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE 
    Year of Incorporation/Organization
    Radio button checkedOver Five Years Ago
    Radio button not checkedWithin Last Five Years (Specify Year)
     
    Radio button not checkedYet to Be Formed
     
      
      
     
    2. Principal Place of Business and Contact Information
    Name of Issuer
     Arcadia Biosciences, Inc.
    Street Address 1Street Address 2
     5956 SHERRY LANE
     SUITE 2000
    CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
     DALLAS
     TEXAS
     
     75225
     214-974-8921 




    3. Related Persons

    Last NameFirst NameMiddle Name
    Schaefer
    Thomas
    J.
    Street Address 1Street Address 2
     5950 Sherry Lane 
     Suite 2000
    CityState/Province/CountryZIP/Postal Code
     Dallas
     TEXAS
     75225
     
    Relationship:Checkbox checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Comcowich
    Kevin
    Street Address 1Street Address 2
     5950 Sherry Lane 
     Suite 2000
    CityState/Province/CountryZIP/Postal Code
     Dallas
     TEXAS
     75225
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Yoder
    Amy
    Street Address 1Street Address 2
     5950 Sherry Lane 
     Suite 200
    CityState/Province/CountryZIP/Postal Code
     Dallas
     TEXAS
     75225
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Murray
    Lilian
    Shackelford
    Street Address 1Street Address 2
     5950 Sherry Lane 
     Suite 2000
    CityState/Province/CountryZIP/Postal Code
     Dallas
     TEXAS
     75225
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     



    Last NameFirst NameMiddle Name
    Waller
    Gregory
    D
    Street Address 1Street Address 2
     5950 Sherry Lane 
     Suite 200
    CityState/Province/CountryZIP/Postal Code
     Dallas
     TEXAS
     75225
     
    Relationship:Checkbox not checkedExecutive OfficerCheckbox checkedDirectorCheckbox not checkedPromoter
    Clarification of Response (if Necessary)
     





    4. Industry Group
     Radio button not checkedAgriculture
    Banking & Financial Services
     Radio button not checked Commercial Banking
     Radio button not checked Insurance
     Radio button not checkedInvesting
     Radio button not checked Investment Banking
     Radio button not checked Pooled Investment Fund

     Radio button not checkedOther Banking & Financial Services
    Radio button not checked Business Services
    Energy
     Radio button not checked Coal Mining
     Radio button not checked Electric Utilities
     Radio button not checked Energy Conservation
     Radio button not checked Environmental Services
     Radio button not checked Oil & Gas
     Radio button not checked Other Energy
    Health Care
     Radio button not checked Biotechnology
     Radio button not checked Health Insurance
     Radio button not checked Hospitals & Physicians
     Radio button not checked Pharmaceuticals
     Radio button not checked Other Health Care
       
       
       
      
    Radio button not checked Manufacturing
    Real Estate
     Radio button not checkedCommercial
     Radio button not checkedConstruction
     Radio button not checkedREITS & Finance
     Radio button not checkedResidential
    Radio button not checkedOther Real Estate
    Radio button not checked Retailing
    Radio button not checkedRestaurants
    Technology
    Radio button not checked Computers
    Radio button not checked Telecommunications
    Radio button checked Other Technology
    Travel
    Radio button not checked Airlines & Airports
    Radio button not checked Lodging & Conventions
    Radio button not checked Tourism & Travel Services
    Radio button not checked Other Travel
    Radio button not checkedOther

      
       
    5. Issuer Size
    Revenue RangeAggregate Net Asset Value Range
    Radio button not checkedNo RevenuesRadio button not checked No Aggregate Net Asset Value
    Radio button not checked $1 - $1,000,000Radio button not checked$1 - $5,000,000
    Radio button not checked $1,000,001 - $5,000,000Radio button not checked $5,000,001 - $25,000,000
    Radio button not checked$5,000,001 - $25,000,000Radio button not checked $25,000,001 - $50,000,000
    Radio button not checked$25,000,001 - $100,000,000Radio button not checked $50,000,001 - $100,000,000
    Radio button not checked Over $100,000,000Radio button not checked Over $100,000,000
    Radio button checked Decline to Disclose Radio button not checkedDecline to Disclose
    Radio button not checked Not ApplicableRadio button not checked Not Applicable

     
    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
    Checkbox not checkedRule 504(b)(1) (not (i), (ii)
    or (iii))
    Checkbox checkedRule 506(b)      
    Checkbox not checkedRule 504 (b)(1)(i) Checkbox not checkedRule 506(c)
    Checkbox not checkedRule 504 (b)(1)(ii) Checkbox not checkedSecurities Act Section 4(a)(5)
    Checkbox not checkedRule 504 (b)(1)(iii)Checkbox not checkedInvestment Company Act Section 3(c)
     
     

    7. Type of Filing
    Checkbox checked New Notice Date of First Sale 
    2026-06-12
    Checkbox not checked First Sale Yet to Occur
    Checkbox not checked Amendment


     
     
    8. Duration of Offering
    Does the Issuer intend this offering to last more than one year? Radio button not checked Yes Radio button checked No
     
     
    9. Type(s) of Securities Offered (select all that apply)
    Checkbox not checkedPooled Investment Fund InterestsCheckbox checkedEquity
    Checkbox not checkedTenant-in-Common Securities Checkbox not checkedDebt
    Checkbox not checkedMineral Property SecuritiesCheckbox checkedOption, Warrant or Other Right to Acquire Another Security
    Checkbox checkedSecurity to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire SecurityCheckbox not checkedOther (describe)
     
     
     
    10. Business Combination Transaction
    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Radio button not checked Yes Radio button checked No
    Clarification of Response (if Necessary)
     
     
     
    11. Minimum Investment
    Minimum investment accepted from any outside investor$
     0
    USD

    12. Sales Compensation
    Recipient Recipient CRD NumberCheckbox not checkedNone
     H.C. Wainwright & Co, LLC
     375
    (Associated) Broker or DealerCheckbox checkedNone(Associated) Broker or Dealer CRD Number Checkbox checkedNone
      
      
    Street Address 1      Street Address 2
    430 Park Avenue
     
    City State/Province/CountryZIP/Postal Code
     New York
     NEW YORK
     10022
    State(s) of SolicitationCheckbox not checkedAll StatesCheckbox not checkedForeign/Non-US
     
    NEW YORK




    13. Offering and Sales Amounts
     
    Total Offering Amount $
    11417964
    USDCheckbox not checkedIndefinite
    Total Amount Sold $
    3999613
    USD
    Total Remaining to be Sold $
    7418351
    USDCheckbox not checkedIndefinite
    Clarification of Response (if Necessary)
    Includes gross proceeds received from issuance of pre-funded warrants & preferred investment options. Offering also reflects the aggregate exercise price of pre-funded warrants, preferred investment options and placement agent investment options issued.
     
    14. Investors

    Checkbox not checkedSelect if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
    Number of such non-accredited investors who already have invested in the offering
       
      Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    5
     
    15. Sales Commissions & Finders’ Fees Expenses
    Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
    Sales Commissions$
    395000
    USDCheckbox not checkedEstimate
    Finders' Fees$
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
    In addition to cash fee, the company paid certain expenses of $75,000 and issued placement agent preferred investment options to purchase up to 271,845 shares of common stock at exercise price $1.2875 per share.
     

    16. Use of Proceeds
    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
     $ 
    0
    USDCheckbox not checkedEstimate
    Clarification of Response (if Necessary)
     

    Signature and Submission
     
    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
    Terms of Submission 
     In submitting this notice, each Issuer named above is: 
     
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
     
    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.
     
    IssuerSignatureName of SignerTitleDate
    Arcadia Biosciences, Inc.Thomas J. SchaeferThomas J. SchaeferCEO2026-06-18




    Get the next $RKDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RKDA

    DatePrice TargetRatingAnalyst
    1/3/2022$7.00 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RKDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kawakami Mark bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 35% to 2,681 units (SEC Form 4)

    4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

    2/5/25 7:34:41 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Chief Executive Officer Schaefer Thomas J. bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 33% to 2,819 units (SEC Form 4)

    4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

    2/5/25 7:24:18 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Chief Financial Officer Kawakami Mark bought $1,442 worth of shares (700 units at $2.06), increasing direct ownership by 55% to 1,981 units (SEC Form 4)

    4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

    8/20/24 8:11:11 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Kawakami Mark

    4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

    5/12/25 8:56:01 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form 4 filed by Chief Executive Officer Schaefer Thomas J.

    4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

    5/12/25 8:48:31 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Chief Financial Officer Kawakami Mark bought $1,743 worth of shares (700 units at $2.49), increasing direct ownership by 35% to 2,681 units (SEC Form 4)

    4 - Arcadia Biosciences, Inc. (0001469443) (Issuer)

    2/5/25 7:34:41 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Arcadia Biosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $6.00 from $7.00 previously

    1/3/22 6:06:17 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    HC Wainwright & Co. reiterated coverage on Arcadia Biosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $7.00 from $6.00 previously

    6/1/21 6:50:30 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Lake Street initiated coverage on Arcadia Biosciences with a new price target

    Lake Street initiated coverage of Arcadia Biosciences with a rating of Buy and set a new price target of $4.50

    5/11/21 12:00:10 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    SEC Filings

    View All

    SEC Form D filed by Arcadia Biosciences Inc.

    D - Arcadia Biosciences, Inc. (0001469443) (Filer)

    6/26/26 4:52:18 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form S-3 filed by Arcadia Biosciences Inc.

    S-3 - Arcadia Biosciences, Inc. (0001469443) (Filer)

    6/26/26 4:32:19 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)

    6/15/26 11:31:39 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

    DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, announced today the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferr

    6/12/26 10:00:00 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

    DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, announced today that it has entered into securities purchase agreements for the purchase and sale of 3,883,496 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock and Series A-2 preferred investment options to purchase up to an aggregate of 3,883,496 shares of common stock at a purchase price of $1.03 per share of common stock (or pre-funded warrant in lieu thereof) and associated preferred investment options in a private placeme

    6/11/26 8:00:00 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights

     -- Zola® volumes increase 18% year-over-year -- -- SG&A at lowest level in Arcadia's history -- DALLAS, May 14, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the first quarter of 2026. "We are very pleased with our performance during the first quarter of 2026," said T.J. Schaefer, CEO of Arcadia. "We were able to bring in gross proceeds of approximately $2.1 million from the exercise of previously outstanding preferred investment options, Zola® coconut water revenues and volumes increased at a double-digit rate compared to the same quarter last year, and o

    5/14/26 4:05:00 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    Leadership Updates

    Live Leadership Updates

    View All

    Arcadia Biosciences (RKDA) Announces Leadership Transition

    -- CEO Stan Jacot replaced by CFO Thomas J. Schaefer -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced that CEO Stan Jacot has left the company and been replaced by Thomas J. Schaefer, effective July 5, 2024. Schaefer was previously Arcadia's chief financial officer and will be replaced in that role by Mark Kawakami, Arcadia's current vice president of finance. "On behalf of Arcadia, I would like to thank Stan for his many contributions to the company," said Board of Directors Chairman Kevin Comcowich. "Under his leadership, Arcadia expanded the GoodWheat brand into three categories, sold the brand to

    7/9/24 8:02:00 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences (RKDA) Appoints Kevin Comcowich to Interim CEO

    DAVIS, Calif., Dec. 20, 2021 /PRNewswire/ -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has appointed Kevin Comcowich, current Chairman of the Arcadia Board of Directors, as interim chief executive officer, effective January 1, 2022, as the board of directors finalizes its search for a permanent CEO. As previously announced on September 7, 2021, the board of directors launched a national search for a new CEO as the company further expands into the consumer packaged goods (CPG) sector.

    12/20/21 10:55:00 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences (RKDA) Appoints Seasoned CPG Sales Executive Brian Schaffer to Senior Vice President of Sales

    DAVIS, Calif., Nov. 22, 2021 /PRNewswire/ --  Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, announced it has named Brian Schaffer as senior vice president of sales, as the company continues to expand its consumer goods platforms. A seasoned sales and general management executive with deep CPG experience, Schaffer has a proven track record of building and leading world class sales organizations. He is tasked with driving the retail launch of Arcadia's GoodWheat brand, a company priority in 2022 as it w

    11/22/21 8:00:00 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    Financials

    Live finance-specific insights

    View All

    Arcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights

    -- Zola® year-to-date revenues increase 26% year over year ---- Arcadia gross profit margins exceed 30% for 11th straight quarter ---- Arcadia cash balance declines by only $257K to $1.1M -- DALLAS, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the third quarter of 2025. "We are very pleased with our performance for the third quarter of 2025." said T.J. Schaefer, CEO of Arcadia. "Zola® coconut water revenues were flat year-over-year in the third quarter as we overlapped the initial sell-in to Zola's largest customer during the third quarter of 2024

    11/7/25 4:05:00 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights

    -- Arcadia revenues increase 11% year over year driven by 24% growth in Zola® -- -- Arcadia receives 2.7 million shares of stock in ABVE -- -- Arcadia eliminates $1M in liabilities -- DALLAS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the second quarter and first half of 2025. "We are very pleased with our performance for the second quarter of 2025," said T.J. Schaefer, CEO of Arcadia. "While our total revenues have increased 11% compared to the second quarter of 2024, Zola® coconut water revenues have grown 24% and once aga

    8/14/25 4:30:00 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business Highlights

    -- Revenues increase 22% year over year driven by 90% growth in Zola® ---- Arcadia sells patents for $750K and eliminates $1M in liabilities ---- Roosevelt agreement amended to provide greater certainty regarding exchange ratio -- DALLAS, May 08, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative, plant-based health and wellness products, today released its financial and business results for the first quarter of 2025. The company has scheduled a conference call at 2:00 p.m. Eastern time (11:00 a.m. Pacific time) to discuss first-quarter results and key strategic achievements. "The momentum we experienced in the second half of 2024 has

    5/8/25 8:02:00 AM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    $RKDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Arcadia Biosciences Inc. (Amendment)

    SC 13G/A - Arcadia Biosciences, Inc. (0001469443) (Subject)

    2/14/24 2:55:48 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form SC 13G filed by Arcadia Biosciences Inc.

    SC 13G - Arcadia Biosciences, Inc. (0001469443) (Subject)

    1/3/24 12:26:00 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples

    SEC Form SC 13G filed by Arcadia Biosciences Inc.

    SC 13G - Arcadia Biosciences, Inc. (0001469443) (Subject)

    2/14/23 1:22:05 PM ET
    $RKDA
    Farming/Seeds/Milling
    Consumer Staples